276 related articles for article (PubMed ID: 20656548)
21. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
[TBL] [Abstract][Full Text] [Related]
22. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
23. Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review.
Muratori L; La Salvia A; Sperone P; Di Maio M
Crit Rev Oncol Hematol; 2019 Jul; 139():41-52. PubMed ID: 31112881
[TBL] [Abstract][Full Text] [Related]
24. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
25. Phospholipid scramblase 1 functionally interacts with angiogenin and regulates angiogenin-enhanced rRNA transcription.
Zhu J; Sheng J; Dong H; Kang L; Ang J; Xu Z
Cell Physiol Biochem; 2013; 32(6):1695-706. PubMed ID: 24356419
[TBL] [Abstract][Full Text] [Related]
26. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
Pollock NI; Grandis JR
Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-induced up-regulation of angiogenin, besides VEGF, is related to progression of oral cancer.
Kishimoto K; Yoshida S; Ibaragi S; Yoshioka N; Okui T; Hu GF; Sasaki A
Oral Oncol; 2012 Nov; 48(11):1120-7. PubMed ID: 22694909
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
29. Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab.
Jouan-Hureaux V; Boura C; Merlin JL; Faivre B
Microvasc Res; 2012 Mar; 83(2):131-7. PubMed ID: 21820450
[TBL] [Abstract][Full Text] [Related]
30. Synthetic Terrein Inhibits Progression of Head and Neck Cancer by Suppressing Angiogenin Production.
Shibata A; Ibaragi S; Mandai H; Tsumura T; Kishimoto K; Okui T; Hassan NM; Shimo T; Omori K; Hu GF; Takashiba S; Suga S; Sasaki A
Anticancer Res; 2016 May; 36(5):2161-8. PubMed ID: 27127118
[TBL] [Abstract][Full Text] [Related]
31. Angiogenin expression in head and neck basaloid and conventional squamous cell carcinoma: a site- and stage-matched comparison.
Marioni G; Staffieri A; Savastano M; Marino F; Giacomelli L; Lionello M; Casotto F; de Filippis C; Blandamura S
J Oral Pathol Med; 2011 Jan; 40(1):55-60. PubMed ID: 20923443
[TBL] [Abstract][Full Text] [Related]
32. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
Stanam A; Gibson-Corley KN; Love-Homan L; Ihejirika N; Simons AL
Oncotarget; 2016 Nov; 7(46):76087-76100. PubMed ID: 27738319
[TBL] [Abstract][Full Text] [Related]
34. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Seiwert TY; Jagadeeswaran R; Faoro L; Janamanchi V; Nallasura V; El Dinali M; Yala S; Kanteti R; Cohen EE; Lingen MW; Martin L; Krishnaswamy S; Klein-Szanto A; Christensen JG; Vokes EE; Salgia R
Cancer Res; 2009 Apr; 69(7):3021-31. PubMed ID: 19318576
[TBL] [Abstract][Full Text] [Related]
35. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.
Blasco MA; Svider PF; Raza SN; Jacobs JR; Folbe AJ; Saraf P; Eloy JA; Baredes S; Fribley AM
Laryngoscope; 2017 Nov; 127(11):2565-2569. PubMed ID: 28581126
[TBL] [Abstract][Full Text] [Related]
37. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
38. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Riedel F; Götte K; Hörmann K; Grandis JR
Adv Otorhinolaryngol; 2005; 62():103-20. PubMed ID: 15608422
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma.
St John MA
Laryngoscope; 2015 Mar; 125 Suppl 3():S1-11. PubMed ID: 25646683
[TBL] [Abstract][Full Text] [Related]
40. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.
Jiffar T; Yilmaz T; Lee J; Hanna E; El-Naggar A; Yu D; Myers JN; Kupferman ME
Oncogene; 2011 Jul; 30(28):3163-73. PubMed ID: 21383688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
